Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed a Form 8-K on December 29, 2025, reporting events occurring on December 23, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Gaithersburg, MD. The filing primarily addresses the execution of a First Amendment to an Asset Purchase Agreement.
Key Financial Metrics and Transaction Details
This filing does not contain standard financial statements, revenue, profit, cash flow, or margin data. The primary financial activity reported is the issuance of equity as part of an asset acquisition payment:
- Equity Issuance: 320,496 shares of Common Stock were issued on December 23, 2025.
- Ownership Impact: The issued shares represent 19.99% of the Company's issued and outstanding Common Stock as of the closing date.
- Valuation: The shares were valued at $1.76 per share, calculated in accordance with the Agreement terms.
- Payment Structure: The equity issuance satisfied a portion of the "First Installment Payment." The remaining balance of this installment is to be paid in cash only.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or year-over-year changes. The material change reported is the consummation of the First Amendment to the Asset Purchase Agreement dated November 20, 2025, involving the accelerated issuance of equity to the Seller (1542770 BC Ltd.) and the Seller Guarantor (ZhiTian (Andy) Zhang).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclosures. The transaction was executed under exemptions from registration under Section 4(a)(2) of the Securities Act, Rule 506(b), and Rule 903 of Regulation S. The Agreement includes customary representations, warranties, and covenants.
Investor Verification Checklist
- Verify the total cash obligation remaining for the First Installment Payment after the equity issuance.
- Confirm the exact dilution impact on existing shareholders given the 19.99% ownership stake transferred to the Seller.
- Review the full text of the First Amendment (Exhibit 10.1) for specific covenants, earn-out provisions, or conditions precedent not detailed in the summary.
- Assess the strategic rationale for the asset purchase and the identity of the assets acquired from 1542770 BC Ltd.